Owen Smith | Investment Director
4Bio Capital

Conference Day 1 - Tuesday 31st March 2020 @ 14:20

Investor panel: How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

• Compare and contrast different VC methodologies
• What other types of innovative funding is there?
• Unorthodox ways to get money
• What do pharma look for when in-licensing?

Dominic Schmidt, Partner, Syncona Investment Management Ltd

×

Dominic Schmidt / Investor panel: How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

Dominic Schmidt, Partner,
Syncona Investment Management Ltd

Dominic is a Partner of Syncona. Prior to joining Syncona, he worked in the life sciences team of strategy consultancy L.E.K. Consulting. Dominic received his PhD from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom ...

CloseMore

Edward Van Wezel, partner, Bgv Biogeneration Ventures

×

Edward Van Wezel / Investor panel: How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

Edward Van Wezel, partner,
Bgv Biogeneration Ventures

Edward currently serves on the supervisory boards of Progentix Orthobiology, Cristal Therapeutics, Synaffix, Staten Biotechnology, Escalier BioSciences and Scenic Biotech. He served on the supervisory boards of BioCeros (sold in 2011), Noviogendix (acquired by MDxHealth) and was founding investor...

CloseMore

Owen Smith, Investment Director, 4Bio Capital

Daniel O'Mahony, Partner, Seroba Life Sciences

×

Daniel O'Mahony / Investor panel: How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

Daniel O'Mahony, Partner,
Seroba Life Sciences

Daniel O’Mahony is a Partner at Seroba Life Sciences and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He...

CloseMore

Christoph Ruedig, Partner, AlbionVC

×

Christoph Ruedig / Investor panel: How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

Christoph Ruedig, Partner,
AlbionVC

Christoph focuses on investments in life sciences and digital health. He initially practised as a radiologist, before spending 3 years at Bain & Company. In 2006, he joined 3i working for their Healthcare Venture Capital after which he worked for General Electric's healthcare...

CloseMore

Alan Muir, Director And Co-Founder, Seven Hills Venture Partners